Aureus
AExcellent

Abbott Laboratories(ABT)

A

Financial data as of Dec 31, 2025Stable · Healthcare

FCF Margin15.2%Free Cash Flow / Revenue
Cash Conversion146.6%Operating CF / Net Income
Free Cash Flow$7.4B
Revenue$44.3B
Net Cash-$5.3BNet debt position
Debt / FCF2.1xManageable debt load
Current Ratio1.58Adequate short-term liquidity
YoY FCF Growth-7.0%5 of 5 quarters positive

How This Grade Was Calculated

Base grade from FCF margin, adjusted by financial health factors

BaseA
→
+0.5Healthy FCF margin with manageable debt (15.2%, 2.1x)
→
FinalA

Analysis Summary

Strengths

  • Strong FCF margin (15.2%)
  • Excellent cash conversion (147%)

Concerns

  • Net debt position ($5.3B) — 2.1x FCF, manageable

Financial Breakdown

Key financials compared side by side

Margin Composition

FCF Margin15.2%
Net Margin14.7%
Operating CF Margin21.6%
CapEx Ratio4.9%

Balance Sheet Health

Debt, liquidity, and leverage snapshot

Net Cash-$5.3BNet debt position
Debt / FCF2.1xManageable debt load
Current Ratio1.58Strong liquidity
Debt / Equity0.27Low leverage

Quarterly FCF Trend

-7.0% YoYStable (-7.0%)

Free cash flow per quarter

Sector Comparison — Healthcare

FCF Margin ranked against sector peers

View all →

Detailed Metrics

Company NameAbbott Laboratories
SectorHealthcare
Free Cash Flow$7.4B
Revenue$44.3B
Net Income$6.5B
Operating Cash Flow$9.6B
Capital Expenditure$2.2B
FCF Margin15.2%
Cash Conversion Rate146.6%
Net Margin14.7%
Total Debt$13.9B
Total Cash$8.5B
Net Cash-$5.3B
Current Ratio1.58
Debt / Equity0.27
Debt / FCF2.1x
YoY FCF Growth-7.0%
Positive Quarters5 of 5
Trend DirectionStable
Report DateDec 31, 2025
GradeA
Data SourceYahoo Finance